Metastatic Pancreatic Cancer Drug on Trial.

 
FREE EXCERPT

A drug that targets enzymes involved in the development of pancreatic cancer cells is showing promise for improved treatment of metastatic pancreatic cancer. The drug, called CPI-613 (known as Devimistat), is being combined with the standard chemotherapy regimen (FOLFIRINOX) to treat pancreatic cancer. The Stony Brook (N.Y.) University Cancer Center has opened a clinical trial with this drug combination to help patients with the disease.

The phase three clinical trial, approved by the Food and Drug Administration, combines CPI-613 with FOLFIRINOX. A previous phase one study showed a median overall patient survival of 20 months with the drug combination, compared to 11 months when treated with chemotherapy alone. That same study showed a tumor response rate--or tumor reduction--of 61% with the combination treatment, compared to nearly 32% with the standard...

To continue reading

FREE SIGN UP